Oral PV-10 Shows Promising Anti-Tumor Activity in Preclinical Bladder Cancer Study
核心洞察
Oral PV-10 monotherapy ranked as the top treatment arm in a seven-arm preclinical bladder cancer study, demonstrating approximately 40% lower tumor burden compared to vehicle control.
Two animals treated with oral PV-10 survived to study end and showed complete absence of gross bladder tumor at necropsy, a finding not observed in any control or anti-PD-1 (搜索) monotherapy animals.
The oral formulation demonstrated excellent tolerability with only 1.9% body weight nadir and no dose-limiting events, positioning it for potential clinical development in multiple cancer indications.
Provectus Biopharmaceuticals (搜索) has reported encouraging preclinical data for oral PV-10, a rose bengal sodium-based immunotherapy, showing significant anti-tumor activity in an orthotopic bladder cancer model. The study, conducted by Translational Drug Development (TD2 Oncology (搜索)), represents the first evaluation of oral PV-10 against solid tumors and marks a potential breakthrough for the company's immunotherapy pipeline.
Study Design and Methodology
The preclinical study utilized an immunologically humanized mouse model, employing UMUC3-Luc luciferase-expressing bladder carcinoma cells implanted orthotopically into the bladder of human peripheral blood mononuclear cell (PBMC)-engrafted NOG mice. This sophisticated model allows evaluation of treatment effects in the presence of a functional human immune compartment, providing clinically relevant insights.
The 45-day study included 54 female mice across seven treatment groups, with tumor progression monitored through bioluminescence imaging. The study arms included no treatment controls, vehicle controls, oral PV-10 monotherapy (2 mg/dose, 5 days on/2 days off), intravesical PV-10 (3 mg/dose weekly), anti-PD-1 (搜索) monotherapy, and combination treatments.
Oral PV-10 Demonstrates Superior Performance
Oral PV-10 monotherapy emerged as the top-ranked treatment arm under a comprehensive scoring framework that assessed anti-tumor response (30%), survival benefit (25%), safety and tolerability (25%), data quality (12%), and translational potential (8%). The oral formulation achieved a weighted total score of 9.24 out of 10, significantly outperforming all other treatment arms.
Key findings for oral PV-10 monotherapy included Day 23 tumor burden approximately 40% lower than vehicle control on a geometric mean basis (log₁₀ mean 10.39 vs. 10.61), and exceptional tolerability with a body weight nadir of only -1.9% across all eight animals. Most notably, one animal in the oral PV-10 monotherapy group survived to study end and showed complete absence of gross bladder tumor at necropsy.
Combination Therapy Shows Promise
The oral PV-10 plus anti-PD-1 (搜索) combination ranked second with a weighted score of 7.84 out of 10. This combination achieved the highest translational potential score, reflecting the established clinical rationale for combining checkpoint blockade with novel immunomodulatory agents in bladder cancer. One long-term survivor in this group also showed absence of gross bladder tumor at necropsy, though the combination was associated with greater toxicity due to anti-PD-1-associated graft-versus-host disease.
Intravesical Route Faces Tolerability Challenges
The intravesical PV-10 arms at 3 mg/dose (30-60 mg/mL concentration) were not tolerated at the tested parameters. Six of seven mice in the intravesical monotherapy group and three of eight mice in the intravesical combination group were lost by Day 12 following the first dosing event, consistent with acute mucosal toxicity. However, researchers noted this represents a maximum tolerated concentration failure rather than a negative efficacy signal, with the intravesical route remaining viable at lower concentrations.
Clinical Development Pathway
"This preclinical study marks three firsts for Provectus: the first evaluation of PV-10 in bladder cancer, the first evaluation of any PV-10 route in an orthotopic tumor model, and the first evaluation of oral PV-10 against a solid tumor cancer," said Dominic Rodrigues, Provectus's President and Vice Chairman of the Board of Directors.
The company's next regulatory milestone involves seeking FDA acceptance of an expanded Investigational New Drug application to permit oral PV-10 human testing. Currently, Provectus has FDA approval for intratumoral administration of PV-10.
"As we consider which indication to pursue first in a Phase 1 study, we are drawn to cancers where the gap between what standard of care offers and what patients need remains widest," said Ed Pershing, Provectus's Chairman and Chief Executive Officer. "Bladder cancer is one such disease. Pancreatic cancer and glioblastoma are others we are watching closely."
Mechanism and Broader Implications
PV-10 is a formulation of pharmaceutical-grade rose bengal sodium, a first-in-class synthetic small molecule from the halogenated xanthene family. The compound's mechanism involves perturbing the tumor microenvironment and driving antitumor immune activity, effects that are not bladder cancer-specific.
"PV-10's mechanism's capacity to perturb the tumor microenvironment and drive antitumor immune activity is not bladder cancer-specific. That is precisely what makes this result scientifically interesting and developmentally promising beyond the indication in which it was observed," Rodrigues noted.
The excellent tolerability profile demonstrated in this study, with no dose-limiting events and minimal weight loss, positions oral PV-10 as a potentially viable treatment option for patients with advanced cancers who may have limited treatment options.